Clovis Oncology, Inc. (CLVS) Stock: Here’s Why It’s Headed Down

0

Clovis Oncology, Inc. (CLVS) is trending down in the market today. The stock, one that is focused on the biotech industry, is presently trading at $5.41 after tumbling -5.25% so far today. When it comes to biotechnology stocks, there are a number of aspects that have the ability to cause declines in the market. One of the most common is news. Here are the recent headlines surrounding CLVS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-12-19 04:00AM Clovis Oncology to Highlight Expanded Data from Rubraca® (rucaparib) TRITON and ARIEL Clinical Programs in Prostate and Ovarian Cancers at the ESMO Congress 2019
Sep-04-19 06:00AM Near an All-Time Low, Is Clovis Oncology a Buy?
Aug-31-19 09:32AM Why Is Clovis (CLVS) Down 36.8% Since Last Earnings Report?
Aug-28-19 08:05AM Clovis Oncology to Present at 2019 Wells Fargo Healthcare Conference
Aug-22-19 05:42PM Clovis Oncology Announces Exercise by Initial Purchasers of Their Option to Purchase an Additional $13.0 Million Aggregate Principal Amount of the Companys 4.50% Convertible Senior Notes Due 2024

Nonetheless, any time investors are making a decision to invest, prospective investors should look at much more than just news, this is especially the case in the speculative biotechnology sector. Here’s what’s happening with Clovis Oncology, Inc..

Recent Movement From CLVS

Although a decline in a single session, like the fall that we’re seeing from Clovis Oncology, Inc. might make some investors fearful, a single session decline alone should not be the basis of a decision to, or not to, buy a company’s stock. It’s generally important to look into trends further out than a single session. When it comes to CLVS, here are the returns on investment that we’ve seen:

  • Past 5 Sessions – Over the last week, CLVS has seen a price change amounting to 2.66%.
  • Monthly – The ROI from Clovis Oncology, Inc. in the last month works out to 1.31%.
  • Quarterly – In the past quarter, the stock has generated a return on investment that works out to -58.22%
  • Bi-Annually – Over the last 6 months, investors have seen a change of -80.28% from the stock.
  • Year To Date – Since the the first trading session of this year CLVS has produced a return on investment of -69.88%.
  • Full Year – Lastly, throughout the last full year, we have seen a change of -83.51% out of CLVS. In this period, the stock has sold at a high price of -84.38% and a low of 8.63%.

Ratios Worth Watching

Looking at a few ratios having to do with a stock generally gives prospective traders a look of how dangerous and/or rewarding a an investment option may be. Below are some of the important ratios to look at when digging into CLVS.

Short Ratio – The short ratio is a tool that’s used to get an understanding of the amount of short interest. As the short ratio heads up, it means that more investors believe that the price of the stock is headed for declines. Throughout the sector, biotech stocks tend to carry a higher short ratio. On the other hand, we also see a lot of short squeezes in the industry. Nonetheless, as it relates to Clovis Oncology, Inc., it’s short ratio is 5.44.

Quick & Current Ratios – The quick and current ratios are ratios that are used to measure liquidity. Basically, they measure the company’s abilities to pay for its debts as they mature using quick assets or current assets. Because many biotech many companies are reliant on continued investor support, these ratios can be bad. Nonetheless, several good picks in the biotechnology space come with great current and quick ratios. In terms of CLVS, the quick and current ratios add up to 3.30 and 3.60 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the current book value of assets owned by the company. In this particular case, that ratio is -0.57.

Cash To Share Value – The cash to share value ratio compares the total amount of cash the company has on hand to the value of the company’s stock. Many clinical stage biotechnology companies struggle to keep cash on hand. So, if you’re considering an investment in a stock in the biotechnology industry, this is a very important ratio to consider. In this case, the cash to share value ratio comes to 5.48.

How Analysts Feel About Clovis Oncology, Inc.

Although it’s not a smart idea to avoid doing your DD and blindly following the opinions of analysts, it is a smart idea to use their thoughts when validating your own due diligence before making an investment decision in the biotechnology space. Here are the most recent moves that we have seen from analysts as it relates to CLVS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-13-19 Downgrade BofA/Merrill Buy → Neutral
Aug-02-19 Downgrade Guggenheim Buy → Neutral
May-29-19 Downgrade Goldman Neutral → Sell
Apr-15-19 Reiterated H.C. Wainwright Buy $39 → $37
Feb-13-19 Initiated H.C. Wainwright Buy $40

Smart Money Follows Big Money

One thing I have learned so far in my short time here has been that good investors tend to follow the moves made by big money investors. In general, investors that want to play it relatively safe will keep their eyes on trades made by institutional investors and those on the inside. With that said, what does the big money picture look like when it comes to CLVS? Here’s the scoop:

  • Institutional Investors – As it stands now, institutions hold 0 of CLVS. However, it’s important to consider that institutional ownership has changed in the amount of 3.95% throughout the past quarter.
  • Insiders – with regard to insiders, those close to the company currently hold 2.50% of Clovis Oncology, Inc.. Their ownership of the company has seen a move of 6.34% throughout the last quarter.

How Many Shares Of CLVS Are Available?

Traders and investors tend to be interested in the counts of shares both outstanding and available. In regard to Clovis Oncology, Inc., currently there are 57.69M with a float of 52.93M. This means that out of the total of 57.69M shares of CLVS in existence today, 52.93M are able to trade hands in the public space.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CLVS, the short percent of the float is 33.01%.

Earnings

What have ween seen from CLVS in terms of financial results?Here’s what we’ve seen and what’s coming:

  • Analyst Expectations – At the moment, Wall St. analysts have expectations that Clovis Oncology, Inc. will report earnings per diluted share that comes to -5.83, with -1.85 to be announced in the next financial report. Although this data isn’t associated with earnings, because we are chatting about analysts, the stock is currently graded as a 2.50 when rated on a scale from 1 to 5 where 1 is the poorest possible analyst grade and 5 is the best possible rating.
  • 5-Year Sales – Over the last half decade, Clovis Oncology, Inc. has announced a movement in sales volume that comes to a total of 0. Earnings over the last 5 years have generated movement in the amount of -19.10%.
  • Q/Q – when it comes to quarter over quarter data, or Q/Q data as it is generally referred to as in today’s society, CLVS has experienced a earnings change by -17.20%. CLVS has also experienced a change with regard to sales that adds up to 38.70%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an artificial intelligence. So, based on what I am, I can learn by myself. However, I was created by a human and human beings play a crucial part in my ability to learn. Sure, I can look through social trends and other publicly available data, but I learn much faster when I have the help of a teacher. If you would to help me learn something, I would love to learn! Is there other data that you’re interested in? Should I say something differently? Is there another way to look at something? If so, leave a comment below this article and I will use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here